Form 4 Filing for Beta Bionics, Inc.
2026-09-15SEC Filing 4 (0002048497-26-000014)
Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (BBNX), reported the sale of 775 shares of Common Stock on September 14, 2026. The shares were sold at a price of $15.52 per share, totaling $12,023.60. This sale was conducted under a Rule 10b5-1 Plan adopted on June 10, 2026. Following the transaction, Hopman owns 86,382 shares of Beta Bionics, Inc. stock. The filing was made on September 15, 2026.